Acorda Therapeutics to Acquire Civitas Therapeutics

From NeurologyWire

Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinsons disease (PD). The acquisition also includes rights to Civitas proprietary ARCUSTM pulmon...

Login to read story

Wednesday, October 22, 2014

Show last days of articles

Research could help improve bladder function among people wi...

From NeurologyWire

People who have suffered spinal cord injuries are often susceptible to bladder infections, and those infections can cause kidney damage and even death...Full story

Zonegran (zonisamide) demonstrates long-term safety and effi...

From NeurologyWire

Zonegran (zonisamide) "continues to be well-tolerated and efficacious when used as long-term monotherapy for the treatment of partial onset seizures i...Full story

Change in step could be sign of early Parkinson's

From NeurologyWire

Researchers at Newcastle University have found what they are calling a "definitive link between gait and early changes in cognitive function in people...Full story

Tuesday, October 21, 2014

Study suggests mental rest and reflection boost learning

From NeurologyWire

Scientists have already established that resting the mind, as in daydreaming, helps strengthen memories of events and retention of information. In a n...Full story

FDA grants Orphan Drug Designation for imaging agent OPS202

From NeurologyWire

OctreoPharm Sciences has received FDA orphan drug designation for its new radiotracer OPS202, based on a next generation antagonistic somatostatin ana...Full story

FDA approves abuse-deterrent labeling for Embeda

From NeurologyWire

FDA has approved new labeling for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release (ER) capsules, an opioid analgesic to treat ...Full story

Therapeutic saline shows promise in treating Alzheimer's and...

From NeurologyWire

Revalesio Corporation and Rush University Medical Center's Department of Neurological Sciences published findings from two research studies that demon...Full story

Monday, October 20, 2014

Results from two Phase III studies added to MS drug's label

From NeurologyWire

The Food and Drug Administration (FDA) has approved the inclusion of efficacy and safety data from the TOWER and TOPIC studies of once-daily, oral Aub...Full story

Friday, October 17, 2014

Creative Minds in Medicine Conference to Launch at Cleveland...

From NeurologyWire

In an effort to bring awareness to the ever-growing link between medicine and the arts, Cleveland-based, Community Partnership for Arts and Culture (C...Full story

Thursday, October 16, 2014

Essential Tremor Foundation Seeks Grant Proposals

From NeurologyWire

The International Essential Tremor Foundation (IETF) is now accepting proposals from those researchers whose investigation addresses the nosology, et...Full story

MS radio will provide tips on pregnancy, exercise and lifest...

From NeurologyWire has launched MS Radio, an audio program. The first episode is a three-part roundtable discussion with four multiple sclerosis nurses from ...Full story

Email reminders to researchers increase p...

From NeurologyWire

Sometimes, all it takes is an email.More researchers will post the results of their trials if they are sent an email reminder according to a study pub...Full story

DEA won't meddle with Cannabidiol production

From NeurologyWire

Insys Therapeutics says its has received DEA approval to manufacture synthetically its pharmaceutical grade Cannabidiol (CBD). The company has also be...Full story

Plan to Prevent Drug Shortages released

From NeurologyWire

ISPE, the International Society for Pharmaceutical Engineering, released its Drug Shortages Prevention Plan at its 2014 Annual Meeting in Las Vegas, N...Full story

Dopamine cell therapy for Parkinson's shows promise

From NeurologyWire

Just one shot of dopamine cells derived from stem cells could be enough to reverse many of the features of Parkinsons disease for decades and the bar...Full story